Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease |
| |
Authors: | Paola Rogliani Luigino Calzetta Maria Gabriella Matera Nicola di Daniele Andrea Girolami Mario Cazzola |
| |
Institution: | 1. Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy;2. Division of Respiratory Medicine, University Hospital “Tor Vergata”, Rome, Italy;3. Department of Experimental Medicine, University of Campania Luigi Vanvitelli, Naples, Italy;4. Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy |
| |
Abstract: | Introduction: Chronic obstructive pulmonary disease (COPD) therapy includes a multi-dimensional approach, taking into account both symptoms of the patient and the number of acute exacerbations of COPD (AECOPDs). There are three main pharmaceutical classes currently available including long-acting muscarinic antagonists (LAMA), long-acting β2-agonists (LABA) and inhaled corticosteroids (ICS). COPD is a major risk factor for most cardiovascular diseases, and cardiac comorbidities are very common in COPD patients. Both LAMA and LABA have a considerable impact on cardiac function by stimulating cardiac β2-adrenergic receptors or inhibiting the heart M2 muscarinic receptors. ICS alone or in combination has never been associated with a real cardiovascular risk. Areas covered: This review explores the data published on the safety of COPD therapy and the implications for current pharmacotherapy. Expert opinion: Several studies have confirmed the good safety profile of bronchodilators available both in monotherapy and in association with other bronchodilators of different classes or with ICS despite the device used. Cardiovascular events in clinical trials are generally low and balanced between groups. The actual cardiovascular risk of fixed-dose combinations (FDCs) in an unselected COPD population will need to be investigated through post-marketing surveillance studies and observational studies. |
| |
Keywords: | COPD LAMA LABA ICS/LABA LABA/LAMA triple therapy cardiovascular safety mortality |
|
|